Replies to post #97072 on Biotech Values

[DewDiligence]

MNTA haven't been able to figure out when/if their own products would get approval…so I find it arrogant and foolish for them to comment on their competitions chances and timing for approval.

That’s a dumb thing to say, wallstarb. Jim Roach commented on the approval chances of Teva’s low-volume Copaxone because I asked him to. Roach gave his personal opinion as an MD, which has absolutely nothing to do with anything Craig Wheeler may have said about when MNTA expects to get FDA approval for generic Lovenox.